Korro Bio doses first cohort in Phase 1/2 ANCHOR trial
Korro Bio has dosed the first cohort in its Phase 1/2 ANCHOR trial of KRRO-121, administering a 2 mg/kg single dose to healthy volunteers.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Korro Bio doses first cohort in Phase 1/2 trial for KRRO-121
Korro Bio has begun dosing the first cohort in its ANCHOR Phase 1/2 program for KRRO-121, an RNA-editing oligonucleotide for hyperammonemia. SAD/MAD studies are underway in healthy volunteers in Australia.